Alemtuzumab: neurological complications

Evidence-based neurology checklist on alemtuzumab: neurological complications: Neuroinflammatory Disseminated necrotising leukoencephalitis Exacerbation of neuroinflammation Progressive multifocal leukoencephalopathy (PML) Vascular Neuromuscular

Neuroinflammatory

  • Disseminated necrotising leukoencephalitis
  • Exacerbation of neuroinflammation
  • Progressive multifocal leukoencephalopathy (PML)

Vascular

Neuromuscular

References

  1. Metz I, Rieckmann P, Kallmann BA, Brück W. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis. Acta Neuropathol Commun 2016; 4:81.
  2. Haghikia A, Dendrou CA, Schneider R, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol 2017; 16:104-106.
  3. Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2019; 25:1196-1201.
  4. Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol 2019; 18:329-331.
  5. FDA Drug Safety Communication. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). FDA website accessed 28 June 2019.
  6. And 7 more. Subscribe to see the full list

Related checklists

Loading...